The Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Osteoarthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoarthritis Market.

Some of the key takeaways from the Osteoarthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Osteoarthritis treatment therapies with a considerable amount of success over the years. 
• Osteoarthritis companies working in the treatment market are Ribomic, BRIM Biotechnology, Meridigen Biotechnology, 4movingbiotech, Eupraxia Pharmaceuticals, Ensol Biosciences Inc., UnicoCell Biomed CO. LTD, Cynata Therapeutics, Biosplice Therapeutics, and others, are developing therapies for the Osteoarthritis treatment 

• Emerging Osteoarthritis therapies in the different phases of clinical trials are- RBM-010, BRM521, UMC119-06-05, 4P-004, EP-104, Engedi1000, Elixcyte, CYP 004, Lorecivivint, and others are expected to have a significant impact on the Osteoarthritis market in the coming years.   
• In November 2022, For the purpose of assessing the effectiveness and safety of a single injection of Lorecivivint 0.07 mg dosage in the target knee joint of participants with moderate to severe osteoarthritis pain of the knee, Biosplice Therapeutics started a Phase III, 16-Week, multicenter, randomised, doubleblind, placebo-controlled trial
• In October 2022, Updates to a Phase II trial examining the efficacy and safety of EP-104IAR for the treatment of knee osteoarthritis (“OA”) were made public by Eupraxia Pharmaceuticals Inc.A clean safety profile and no drug-related Serious Adverse Events were detected in Eupraxia’s current Phase II research, which has successfully completed all DSMB reviews, according to the company’s announcement
• In September 2022, A licence agreement between KiOmed Pharma and Hansoh Pharmaceutical Group Company Limited was made public in order to develop and market KiOmedinevsOne, a carboxymethyl chitosan injection that has been approved for use in Europe to treat knee osteoarthritis, in mainland China, Macau, and Taiwan (the territory).According to the terms of the contract, KiOmed will receive a down payment, be eligible for milestone payments of up to € 66 million in research, regulatory, and commercial activities, as well as tier-based royalties on future product sales
• In September 2022, Pluri Inc. reported that PROTO (Advanced Personalised Therapies for Osteoarthritis), an international partnership lead by Charité, Berlin Institute of Health Centre for Regenerative Therapies, had received a €7.5 million non-dilutive grant from the European Union’s Horizon Europe programme. The PROTO initiative seeks to treat mild to moderate knee osteoarthritis (OA) using Pluri’s PLX-PAD cells in a Phase I/IIa research
• In September 2021, A Phase II, randomised, double-blind, vehicle-controlled trial was started by Eupraxia Pharmaceuticals Inc. to examine the safety, effectiveness, and pharmacokinetics of EP-104IAR in a single dose over the course of 24 weeks in patients with knee osteoarthritis
• In September 2021, Biosplice Therapeutics and Haisco Pharmaceutical Group Co., Ltd. announced the execution of alicensing agreement that grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for thetreatment of knee osteoarthritis (“OA”) and other musculoskeletal conditions in China.

Osteoarthritis Overview

The most typical type of arthritis is osteoarthritis (OA). Some people refer to it as “wear and tear” arthritis or degenerative joint disease. It usually affects the hands, hips, and knees. A joint’s cartilage starts to degrade and the underlying bone starts to change as a result of OA. 

Get a Free Sample PDF Report to know more about Osteoarthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight

Emerging Osteoarthritis Drugs Under Different Phases of Clinical Development Include:

• RBM-010: Ribomic
• BRM521: BRIM Biotechnology
• UMC119-06-05: Meridigen Biotechnology
• 4P-004: 4movingbiotech
• TTAX03: Tissue Tech
• SMUP-IA-01: Medipost
• JTA-004: Bone Therapeutics
• EP-104: Eupraxia Pharmaceuticals
• Engedi1000: Ensol Biosciences Inc.
• Elixcyte: UnicoCell Biomed CO. LTD
• CYP 004: Cynata Therapeutics
• Lorecivivint: Biosplice Therapeutics

Route of Administration

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Osteoarthritis Pipeline Therapeutics Assessment

• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage and Product Type
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis By Stage and Route of Administration
• Osteoarthritis Assessment by Molecule Type
• Osteoarthritis by Stage and Molecule Type

DelveInsight’s Osteoarthritis Report covers around 130+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoarthritis product details are provided in the report. Download the Osteoarthritis pipeline report to learn more about the emerging Osteoarthritis therapies

Some of the key companies in the Osteoarthritis Therapeutics Market include:

Key companies developing therapies for Osteoarthritis are – Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, and others.

Osteoarthritis Pipeline Analysis:

The Osteoarthritis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.
• Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteoarthritis drugs and therapies

Osteoarthritis Pipeline Market Drivers

• Increase in prevalence of Osteoarthritis, rising geriatric population are some of the important factors that are fueling the Osteoarthritis Market.

Osteoarthritis Pipeline Market Barriers 

• However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Osteoarthritis Market growth.

Scope of Osteoarthritis Pipeline Drug Insight    

• Coverage: Global
• Key Osteoarthritis Companies: Ribomic, BRIM Biotechnology, Meridigen Biotechnology, 4movingbiotech, Eupraxia Pharmaceuticals, Ensol Biosciences Inc., UnicoCell Biomed CO. LTD, Cynata Therapeutics, Biosplice Therapeutics, and others
• Key Osteoarthritis Therapies: RBM-010, BRM521, UMC119-06-05, 4P-004, EP-104, Engedi1000, Elixcyte, CYP 004, Lorecivivint, and others
• Osteoarthritis Therapeutic Assessment: Osteoarthritis current marketed and Osteoarthritis emerging therapies
• Osteoarthritis Market Dynamics: Osteoarthritis market drivers and Osteoarthritis market barriers 

Request for Sample PDF Report for Osteoarthritis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services